|
中國生物製藥有限公司, 01177.HK - 綜合損益表 |
2021-12 |
2020-12 |
2019-12 |
2018-12 |
2017-12 |
2016-12 |
2015-12 |
2014-12 |
2013-12 |
2012-12 |
2011-12 |
2010-12 |
2009-12 |
2008-12 |
2007-12 |
2006-12 |
2005-12 |
營業額 |
26,861,356 |
23,647,224 |
24,234,030 |
20,888,584 |
14,819,302 |
15,825,438 |
14,550,225 |
12,378,350 |
9,901,196 |
7,496,888 |
5,782,337 |
4,086,144 |
3,234,975 |
2,282,213 |
1,164,274 |
734,652 |
1,235,911 |
經營溢利 |
4,941,883 |
5,016,277 |
5,579,207 |
11,369,171 |
3,786,763 |
3,395,656 |
3,118,630 |
2,464,415 |
1,898,508 |
1,482,428 |
999,880 |
1,088,941 |
798,546 |
600,263 |
342,100 |
204,369 |
356,175 |
非經營/ 特殊項目 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1,339,876 |
聯營公司 |
13,630,790 |
-3,233 |
111,385 |
59,910 |
409,076 |
347,623 |
325,254 |
336,792 |
238,002 |
240,179 |
-4,122 |
-1,426 |
929 |
0 |
216 |
704 |
0 |
除稅前經營溢利 |
18,572,673 |
5,013,044 |
5,690,592 |
11,429,081 |
4,195,839 |
3,743,279 |
3,443,884 |
2,801,207 |
2,136,510 |
1,722,607 |
995,758 |
1,087,515 |
799,475 |
600,263 |
342,316 |
205,073 |
1,696,051 |
稅項 |
1,957,880 |
672,377 |
902,747 |
696,236 |
542,292 |
555,019 |
532,876 |
440,153 |
354,551 |
305,135 |
166,519 |
228,146 |
135,028 |
118,260 |
33,972 |
22,106 |
43,447 |
少數股東權益 |
2,006,381 |
1,569,581 |
2,026,303 |
1,686,498 |
1,482,596 |
1,274,984 |
1,132,316 |
847,849 |
745,195 |
526,714 |
366,438 |
292,472 |
267,485 |
184,388 |
83,991 |
41,795 |
119,675 |
股東應占溢利 |
14,608,412 |
2,771,086 |
2,761,542 |
9,046,347 |
2,170,951 |
1,913,276 |
1,778,692 |
1,513,205 |
1,036,764 |
890,758 |
462,801 |
566,897 |
396,962 |
297,615 |
224,353 |
141,172 |
1,532,929 |
貨幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
人民幣 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
港元 |
單位 |
千 |
千 |
千 |
千 |
千 |
千 |
千 |
主要項目 |
折舊 |
992,556 |
1,654,836 |
1,446,211 |
1,176,124 |
343,389 |
394,338 |
353,310 |
259,490 |
223,943 |
179,387 |
135,946 |
82,244 |
58,377 |
39,894 |
27,855 |
21,567 |
20,153 |
利息 |
308,617 |
323,368 |
229,950 |
153,264 |
77,945 |
89,563 |
79,812 |
43,096 |
2,500 |
9,650 |
11,289 |
5,804 |
2,773 |
9,135 |
2,575 |
2,205 |
3,461 |
利息撥作發展資本 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
處置/重估固定資產 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
稅率(%) |
10.54 |
13.41 |
15.86 |
6.09 |
12.92 |
14.83 |
15.47 |
15.71 |
16.59 |
17.71 |
16.72 |
20.98 |
16.89 |
19.7 |
9.92 |
10.78 |
2.56 |
營業額增長(%) |
13.59 |
-2.42 |
16.02 |
40.96 |
-6.36 |
8.76 |
17.55 |
25.02 |
32.07 |
29.65 |
41.51 |
25.97 |
41.75 |
96.02 |
58.48 |
-40.56 |
17.66 |
股東應占溢利增長(%) |
427.17 |
0.35 |
-69.47 |
316.7 |
13.47 |
7.57 |
17.54 |
45.95 |
16.39 |
92.47 |
-18.36 |
42.81 |
33.38 |
32.65 |
58.92 |
-90.79 |
810.63 |
核數師意見 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
說明:1代表無保留意見;2代表保留意見;3代表修改意見
|
|